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Aims:Wehave shown that diabetes causes cerebrovascular remodeling inpart by the activation of the endothelin
(ET-1) system in a glucose-dependent manner. We also reported increased yet dysfunctional cerebral angiogen-
esis in diabetes. Here, we tested the hypothesis that dual ET-1 receptor antagonism or glycemic control can
reverse already established diabetes-induced vascular remodeling and neovascularization.
Main methods: 18-week non-obese type-2 diabetic Goto-Kakizaki (GK) were treated with vehicle, metformin
(300 mg/kg/day) or bosentan (100 mg/kg/day) for 4 weeks by oral gavage and compared to 10 and 18-weeks
GK rats. Isolated middle cerebral artery (MCA) lumen diameter (LD), media thickness (MT), media:lumen
(M:L) ratio, and cross-sectional area (CSA)weremeasuredusingpressurized arteriograph. Assessment of remod-
eling and angiogenesis in the brain parenchyma was achieved by three-dimensional reconstruction of ﬂuores-
cently labeled images of the vasculature acquired by confocal microscopy, and measurement of
neovascularization indices including vascular volume and surface area, branch density and tortuosity.
Key ﬁndings:MCA remodeling (increasedM:L ratio and CSA, but decreased LD) occurred by 18 weeks and did not
progress by 22 weeks in diabetic GK rats. Metformin and bosentan partially corrected large artery remodeling.
Both treatments signiﬁcantly reduced all indices of neovascularization compared to untreated diabetic rats.
Signiﬁcance:Glycemic control or ET-1 antagonism can partially reverse diabetes-induced cerebrovascular remod-
eling and neovascularization. These results strongly suggest that either approach offers a therapeutic beneﬁt and
combination treatments need to be tested.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Diabetes is a growing problem worldwide. In the United States
alone, 25.8 million patients have diabetes and suffer from devastating
complications such as cardiovascular disease, diabetic retinopathy,
nephropathy, and neuropathy (Standards of medical care in diabetes,
2011; Giacco and Brownlee, 2010). Diabetes targets vasculature, and
pathological changes that occur in vascular function and structure are
the main mechanisms contributing to these complications. While
cerebral complications of diabetes are less understood, it is known
that diabetes increases the risk and severity of stroke and cognitive
impairment (Ergul et al., 2009; Roger et al., 2012). In this context, regu-
lation of cerebrovascular function and structure is critical to maintain
constant blood ﬂow to the brain.
Our studies in Goto-Kakizaki rats, a lean type II diabetes animal
model, have illustrated a crucial involvement of the endothelin (ET-1)eorgia Regents University, 1120
21 9103; fax:+1706 721 7299.
. This is an open access article undersystem in diabetes-induced cerebrovascular remodeling (Li et al.,
2010). We showed that diabetes caused hypertrophic remodeling of
middle cerebral arteries (MCA) with increased wall thickness and wall
to lumen ratio as the disease progresses (Harris et al., 2005). The vascu-
lar remodeling was associated with impaired myogenic reactivity and
decreased cerebral blood ﬂow (Kelly-Cobbs et al., 2011b). Our results
also showed that hyperglycemia-mediated upregulation of the ET
system plays a critical role in the development of vascular remodeling
where glycemic control or dual ET-1 antagonism prevented diabetes-
induced remodeling (Kelly-Cobbs et al., 2011a, 2011b; Li et al., 2010;
Sachidanandam et al., 2009a). Accordingly, the ﬁrst goal of this study
was to determine whether and to what extent this remodeling con-
tinues to progress and whether it can be reversed if treatment is started
late in the disease.
Recently, we expanded these studies and showed that cerebrovas-
cular remodeling that occurs in diabetes is not limited to large vessels
but also includes smaller vessels penetrating deep into the brain tissue.
We speciﬁcally showed that there is increased neovascularization in
diabetic brain as demonstrated by greater vascular density and volume
aswell as remodeling as evidenced by greater branchdensity, tortuositythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
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2013, 2012). Interestingly, these changes in smaller vessels occurred
shortly after onset of diabetes at 10 weeks of age, at which time point
we do not see structural changes in large vessels like MCAs (Kelly-
Cobbs et al., 2011a, 2011b). Given that this increased neovascularization
response resulted in formation of dysfunctional and leaky new vessels,
prevention of this pathological neovascularization and/or improvement
of thematuration of the cerebrovasculature holds therapeutic potential.
ET-1 has been shown to contribute to pathological angiogenesis that
occurs in cancers. Thus, the second goal of this study was to determine
whether ET-1 contributes to cerebral neovascularization in our model
by investigating the impact of ET receptor antagonism on established
pathological neovascularization.
Methods
Animals
All experiments were performed using male diabetic GK rats
(In-house bred, derived from the Tampa colony or purchased from
the Tampa colony, Taconic; Hudson, NY). The animals were housed at
the Georgia Regents University animal care facility that is approved by
the American Association for Accreditation of Laboratory Animal Care.
All protocols were approved by the institutional animal care and use
committee. Animals were fed standard rat chow and tap water ad
libitum. Body weights and blood glucose measurements were taken bi-
weekly. Blood glucose (BG) measurements were taken from tail vein
samples using a commercially available glucometer (Freestyle, Abbott
Diabetes Care, Inc; Alameda, CA). Mean arterial pressure (MAP,
mmHg) was measured using the tail-cuff method. All animals were
anesthetized with pentobarbital sodium (Fatal-Plus, Vortech Pharma-
ceuticals Ltd; Dearborn, MI), exsanguinated via cardiac puncture, and
decapitated to extract the brain. BG andMAP are represented in Table 1.
Animal treatments
To determine whether dual ET receptor antagonism by bosentan or
glycemic control bymetformin reverses established cerebrovascular re-
modeling and dysfunction, GK rats were assigned randomly into 3
groups and treated with vehicle, metformin (300 mg/kg/day) or dual
ET-1 receptor antagonist bosentan (100 mg/kg/day). Treatment started
at 18 weeks of age after the development of diabetes-induced cerebro-
vascular remodeling and neovascularization for 4 weeks by oral gavage.
Additional groups include vehicle-treated 10 or 18-weeks GK rats to
determine the progression of vascular changes.
Remodeling parameters
MCAs were quickly excised and used within 45 min of isolation to
ensure viability of the vessels. A pressure arteriograph system (Living
Systems; Burlington, VT) was used to evaluate the MCA structure. For
these studies, MCA segments approximately 200–250 μm in diameter
and proximal to the junction between theMCA and the inferior cerebral
vein were used exclusively. The vessels were ﬁrst mounted onto glass
cannulas in an arteriograph chamber and HEPES bicarbonate buffer
(in mM: 130 NaCl, 4 KCl, 1.2 MgSO4, 4 NaHCO3, 10 HEPES, 1.18Table 1
Animal characteristics.
Control Diabetes
Body weight (g) 443 ± 14 371 ± 5⁎
Blood glucose (mg/dl) 112 ± 9 228 ± 26
Mean arterial pressure (mmHg) 97.6 ± 4 108 ± 5
⁎ p b 0.05 vs control.KH2PO4, 5.5 glucose, 1.8 CaCl2) was circulated and maintained at
37 ± 0.5 °C. The MCA segments were then pressurized at 60 mmHg
for 1 h to generate spontaneous tone. A video dimension analyzer con-
nected to the arteriograph system was used to measure wall thickness
(WT) and lumen diameter (LD) at 80 mmHg. Vessel passive properties
weremeasured in Ca2+-free buffer with the addition of 10−7 M papav-
erine hydrochloride.Data calculations
Using the WT and LD measurements obtained in active conditions
(in the presence of Ca2+) and in passive conditions (in the absence of
Ca2+), the following parameters related to MCA structure can be
calculated:Media Thickness (MT, μm) = Left Wall + Right Wall; Outer
Diameter (OD, μm) = LD + MT, ratio Medial/Lumen (M/L) = MT/LD
and Cross sectional area = Area of the vessel− area of the lumen.Assessment of neovascularization parameters
Vascularization patterns and density were measured using the
space-ﬁlling FITC-Fluorescein Iso-ThioCyanate-dextran method as we
recently described (Prakash et al., 2012). Brains were processed in 4%
paraformaldehyde (24 h) and 30% sucrose in phosphate-buffered saline
(PBS), sectioned into 100 μm slices and mounted on slides. Z-stacked
confocal images of the regions proximate to the middle cerebral artery
(MCA) and its branches that supply the frontal motor cortex (bregma
1 to−1) were acquired using Zeiss LSM 510 upright confocal micro-
scope. Cortical parenchymal vessels that dive in from the surface vessels
and its immediate ﬁrst order branches were imaged at 10 × in this
region. Amean of 3 values from this regionwas recorded as an observa-
tion. Each measurement from one animal was comprised of an average
of 9 images from either the cortical or the striatal region.
Vascular volume refers to the ratio of the volume of the vasculature
to the total volume (reference volume) of the section on a Z-stack.
Surface area represents the absolute surface area of the vasculature,
and a proportional increase in surface area with vascular volume repre-
sents increased vasculature. Vascular density refers to the density of
FITC-stained vasculature from the merged planes over the total area of
the section. This parameter determines the change in vascularization
in a given reference area and is independent of Z-function. Morphome-
try was assessed using Fiji software and axially projected into 8-bit
stacked images. Branch density refers to the number of branch points
found over unit length of a vessel. For vessel tortuosity, the centerline
line extracted images were analyzed by longest–shortest distance
methodwithout pruning the ends in order to measure the actual length
of the vessels.Statistical analysis
One-way ANOVA was used to compare groups. A Tukey's adjust-
ment formultiple comparisonswas used for all post-hocmean compar-
isons for signiﬁcant effects from all analyses. Data was expressed as
Mean ± SEM and p b 0.05 was considered signiﬁcant.Diabetes + metformin Diabetes + bosentan
371 ± 6⁎ 377 ± 12⁎
⁎ 126 ± 5 199 ± 20⁎
105 ± 5 120 ± 5⁎
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Fig. 1. Endothelin receptor antagonist or glycemic control partially reverses established
MCA remodeling in diabetes. Diabetic GK rats were treated with vehicle, bosentan
(100 mg/kg/day), or metformin (300 mg/kg/day) from 18 to 22 weeks after established
diabetes. At termination, arteriograph was used to assess MCA structure and results at
80 mmHg pressure, which is the average pressure these vessels are exposed to in vivo,
are shown diabetic animals developed increased MT (A), M:L (C), and CAS (D) by
18 weeks of age, but there was no change in passive lumen diameter (C). Both glycemic
control with metformin or dual endothelin receptor antagonism with bosentan partially
reversed vascular remodeling by decreasing the MT, M:L ratio, and CSA. (Mean ± SEM
(n= 6–8, *p b 0.01 vs D10W, #p b 0.01 vs D22W and ##p b 0.001 vs D22W).
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Metabolic parameters
Whilemetformin treatment did not have an effect on blood pressure
in diabetic rats, bosentanmildly elevated blood pressure thatwas signif-
icant from vehicle treated rats (Table 1). While metformin treatment
normalized blood glucose, bosentan had slightly reduced the blood glu-
cose of GK rats. This effect was not signiﬁcant from the GK rats treated
with the vehicle.
Effect of dual endothelin receptor blockade or glycemic control on
established MCA remodeling in diabetes
Media thickness was increased by 18 weeks as we previously
reported. There was no further change by 22 weeks (Fig. 1A). Passive
lumen diameter was similar among the groups (Fig. 1B). M:L ratio
(Fig. 1C) and CSA (Fig. 1D) followed a similar pattern and were in-
creased to a similar degree in both 18 and 22 week-old diabetic rats
as compared to 10 week old diabetic rats. Both the glycemic control
with metformin or the dual endothelin receptor antagonism with
bosentan partially reversed the established vascular remodeling by
decreasing the MT, M:L ratio, and CSA (Fig. 1A–D).
Effect of dual endothelin receptor blockade or glycemic control on
established cerebral neovascularization in diabetes
The cortical and striatal regions in the brain that are susceptible to
vascular injury when animals are subjected to focal brain ischemia
were chosen to assess vascular measurements as we have reported be-
fore (Prakash et al., 2012). Total vascular density, volume, and surface
area in cortex and striatumwere similar in both 10 and 22 week-old di-
abetic rats (Fig. 2A–D), suggesting that the pathological neovasculariza-
tion we reported earlier does not further progress as disease duration
increases. Metformin and bosentan treatment reversed diabetes-
induced neovascularization as demonstrated by decreased vascular
volume, vascular density, and surface area (Fig. 2 B–D) as compared to
untreated diabetic rats in both cortical and striatal areas.
Effect of dual endothelin receptor blockade or glycemic control on
established small vessels remodeling in diabetes
Similar to neovascularization indices, branch density and tortuosity
remained unchanged from 10 to 22 weeks (Fig. 3). Treatment with
metformin or bosentan showed signiﬁcant reduction in branching and
tortuosity when compared to untreated diabetic rats (Fig. 3B–C).
Discussion
The current study presents novel information that diabetes-induced
vascular remodeling and neovascularization could be reversed using
dual endothelin antagonism or glycemic control. Our results showed
that 1) small vessel remodeling and neovascularization that occurs
early in the disease progress stabilizes and does not further progress,
and 2) both glycemic control by metformin or endothelin antagonism
by bosentan can reverse diabetes-mediated changes in the cerebrovas-
cular structure and organization.
We and others have reported that as diabetes progresses, there
is signiﬁcant vascular remodeling characterized by increased MT, L:R,
and vascular CSA in various vascular beds (Bailey, 2008; Harris et al.,
2005; Kelly-Cobbs et al., 2011a; Sachidanandam et al., 2010). Within
the cerebrovasculature, this remodeling was associated with impaired
myogenic reactivity, decreased tone, and decrease in cerebral blood
ﬂow (Kelly-Cobbs et al., 2011a). We have recently showed that glyce-
mic control with metformin or dual receptor antagonism by bosentan
can prevent large artery remodeling and improves myogenic function(Li et al., 2010; Sachidanandam et al., 2008; Sachidanandam et al.,
2009b; Sachidanandam et al., 2010). While these results provided im-
portant information with regard to use of these agents for preventive
strategies in diabetes, the therapeutic potential remained undeﬁned
and the current study now provides evidence that established
ACortex Striatum
0
5
10
15
20 D 10 W
D 22 W
D 22 W+ Bosentan
D 22W+ Metformin
**
%
 S
ur
fa
ce
 A
re
a
*
Cortex Striatum
0
5
10
15
20
D 10 W
D 22 W
D 22W+ Bosentan
D 22 W+ Metformin
**
%
 V
as
cu
la
r V
ol
um
e
*
Cortex Striatum
0
20
40
60 D 10 W
D 22 W
D 22 W+ Bosentan
D 22W+ Metformin
**
*
%
 V
as
cu
la
r D
en
si
ty
D
Co
rte
x
St
ria
tu
m
D 22 W D+ BosentanD 10 W D+Metformin
C
B
Fig. 2. Endothelin receptor antagonism or glycemic control partially reverses established neovascularization in diabetes. At termination, rats were injected with FITC-dextran to ﬁll and vi-
sualize blood vessels. Images acquired by confocal microscopy were used for 3-dimensional reconstruction of the cerebrovascular network for measurement of vascular density, vascular
volume, and surface area in the cortical and striatal regions using Volocity software. Representative images are given on panel (A) and average data are shown in histograms on Panels
(B–D). No signiﬁcant changes were detected between 22-week compared to 10-week GK rats. Metformin and bosentan treatments signiﬁcantly reduced vascular volume, vascular density,
and surface area as compared to vehicle-treated 22 weeks diabetic rats (Results are expressed as mean ± SEM, n = 6–8, **p b 0.001 and *p b 0.01 vs D 22 Week).
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Fig. 3. Endothelin receptor antagonism or glycemic control partially reverses established small vessel remodeling of the brain in diabetes. Confocal images used for vascular density mea-
surements in Fig. 2 were converted to binary mode and skeletonized using ImageJ software to determine branch density and tortuosity in the cortex area. (A) Representative binary and
skeleton images of brain section of GK rats treated with vehicle, bosentan, or metformin. Metformin and bosentan treatment signiﬁcantly reduced branch density (B) and tortuosity
(C) compared with vehicle-treated 22 weeks GK rats (Results are expressed as mean ± SEM, n = 6–8, **p b 0.001 and *p b 0.01 vs D 22 weeks).
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these approaches. Given that blood ﬂow is inversely correlated to the
lumen diameter, and large arteries like MCA contribute signiﬁcantly to
regulation of cerebrovascular resistance and hence cerebral blood
ﬂow, any improvement of the vascular structure is likely to provide
therapeutic beneﬁt (Faraci and Heistad, 1990; Palomares and Cipolla,
2011).
While the effect of diabetes on function and structure of isolated and
relatively larger arteries has been reported by numerous groups, the im-
pact of diabetes on cerebral neovascularizationwas not explored until re-
cently. In a series of studies, we have shown that diabetes causesincreased, yet dysfunctional neovascularization in the cerebrovasculature
of diabetic GK rats. We reported increased vascular density, volume, and
surface area in the brain parenchyma which progressively increased
from front to the back of the brain in diabetic animals as compared to
age-matched controls (Prakash et al., 2012). This augmented angiogene-
sis was associatedwith poor vessel wall maturity as indicated by reduced
pericytes and increased non-perfused vessels and permeability. These
pathological changes occurred quite early in the disease, i.e., within
5–6 weeks after the onset of diabetes, in the cerebrovasculature and in
the retina but not in the peripheral vasculature. Our most recent study
demonstrated similar changes in yet another model of diabetes, db/db
273M. Abdelsaid et al. / Life Sciences 118 (2014) 268–273mice, suggesting that this pathological neovascularization is not unique to
the GK model of diabetes and may have a broader impact in diabetes.
While mechanisms contributing to cerebral neovascularization in diabe-
tes are not fully understood, it iswidely accepted that vascular endothelial
growth factor (VEGF-A) plays a central role in the regulation of neovascu-
larization. We have shown that VEGF-A is the critical factor that stimu-
lates angiogenic properties of brain microvascular endothelial cells
isolated from diabetic animals. Recent studies showed that ET-1, through
the regulation of hypoxia-inducible factor and VEGF-A, contributes to
tumor angiogenesis,which is yet anothermodel of pathological angiogen-
esis Garrafa et al. (2012); Spinella et al., 2010). In the current study, we
nowprovide evidence that ET receptor antagonism reduces vascular den-
sity and volume. It is highly likely that ET-1, either through direct effects
on the VEGF system and/or through the regulation of cerebrovascular
function and blood ﬂow, may be involved in the pathological remodeling
and neovascularization that occurs in the brain in diabetes. However, the
mechanisms by which ET-1 contributes to pathological angiogenesis and
the impact of ET receptor antagonism on vessel maturation and perme-
ability remain to be determined.
The current study has minor limitations. First, we used treatment
with metformin or bosentan only in diabetic animals because our goal
was to determine whether we can reverse established remodeling and
neovascularization in diabetes. Additionally, our group previously
showed that diabetes-induced neovascularization andMCA remodeling
occurs by 10 and 18 weeks of age, respectively, in diabetic rats com-
pared to the age matched control rats (Prakash et al., 2012, 2013). We
recognize that comparison of results obtained in the treatment groups
to an untreated control group would have allowed us to determine
whether these interventions completely or partially reverse these path-
ological changes, and needs to be included in future studies. Second, it is
noteworthy tomention that bosentan treatment slightly but signiﬁcant-
ly increases blood pressure. In our previous studies with younger ani-
mals we reported a similar increase using both tail-cuff and telemetry
approaches to measure blood pressure (Kelly-Cobbs et al., 2011b; Li
et al., 2011). While we do not have an explanation for this ﬁnding as
bosentan has been reported to lower blood pressure in other studies in-
volving hypertensive animal models, observed blood pressure is similar
to what we have reported with selective ETB blockade (Kelly-Cobbs
et al., 2011b; Li et al., 2011). Another possibility is that the renal ET sys-
tem is altered in diabetic rats, contributing to elevated blood pressure
with treatment. Nevertheless, despite this blood pressure increase,
bosentan provides vasculoprotection and partially reverses these
changes in the large and smaller vessels in the brain in a comparable
manner to metformin.
In conclusion, glycemic control or ET-1 antagonism can reverse
established cerebrovascular remodeling and pathological neovasculari-
zation. These results strongly suggest that either approach offers a
therapeutic beneﬁt for patients with established diabetic vascular
complications.Conﬂict of interest statement
Wewish to conﬁrm that there are no known conﬂicts of interest associated with this
publication and there has been no signiﬁcant ﬁnancial support for this work that could
have inﬂuenced its outcome.
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